Latest Breaking News On - Atossa therapeutics inc - Page 1 : comparemela.com

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

SEATTLE, May 28, 2024 Atossa Therapeutics, Inc. , today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk.

Eric van zantenKarolinska institutetAtossa therapeutics incDepartment of medical epidemiologyExchange commissionGlobenewswire incProfound artificial intelligenceRisk assessment modelPer hallMedical epidemiologyPrincipal investigatorBreast cancer risk assessment toolChief executiveSelective estrogen receptor modulatorPrivate securities litigation reform actStock market

Atossa Therapeutics to support AI-based breast cancer risk study

Atossa Therapeutics to support AI-based breast cancer risk study
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Karolinska institutetAtossa therapeutics incPrincipal investigatorSteven quay

Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1 13

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.13 and traded as high as $1.55. Atossa Therapeutics shares last traded at $1.46, with a volume of 1,163,998 shares traded. Wall Street Analysts Forecast Growth […]

Jonathan finnConnor clark lunn investment management ltdCetera advisorsAtossa therapeutics company profileAtossa therapeutics incVanguard group incVirtu financialCantor fitzgeraldSecurities exchange commissionAtossa therapeuticsGet free reportDirector jonathan finnExchange commissionLunn investment managementAtossa therapeutics daily

Cantor Fitzgerald Reiterates Overweight Rating for Atossa Therapeutics (NASDAQ:ATOS)

Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research note published on Tuesday morning, Benzinga reports. A number of other brokerages have also weighed in on ATOS. HC Wainwright lifted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company […]

Jonathan finnCantor fitzgeraldConnor clark lunn investment management ltdAtossa therapeutics incAtossa therapeutics company profileVanguard group incAtossa therapeuticsFree reportGet free reportDirector jonathan finnLunn investment managementAtossa therapeutics daily

StockNews com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. A number of other research analysts have also recently commented on ATOS. HC Wainwright boosted their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the […]

Jonathan finnSecurities exchange commissionVanguard group incAtossa therapeutics incConnor clark lunn investment management ltdCantor fitzgeraldAtossa therapeutics company profileAtossa therapeuticsFree reportGet free reportDirector jonathan finnExchange commissionLunn investment managementVanguard groupAtossa therapeutics daily